To Evaluate the Safety and the Pharmacokinetics of NVP-2203

Phase 1 Study to Evaluate the Safety and the Pharmacokinetics of NVP-2203 in Healthy Adult Volunteers

The purpose of this study is to evaluate the safety and pharmacokinetics after administration of NVP-2203.

Phase 1 to evaluate the safety and pharmacokinetics after administration of NVP-2203.

Inclusion Criteria:

• Healthy adult subjects who signed informed consent
• BMI of >18.0 kg/m2 and <30.0 kg/m2 subject, weight more than 50kg(45 kg or more for woman)

Exclusion Criteria:

• Subjects participated in another clinical trial within 6 months prior to administration of the study drug
• Inadequate subject for the clinical trial by the investigator's decision